1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Playing the CRO long game?

Discussion in 'Quintiles' started by anonymous, Feb 12, 2017 at 6:06 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    How deep does the IMS merger needs to go before QuintilesIMS divests the R&D element and drops being a CRO from their portfolio?

    R&D is looking more and more like a pure-Novella org these days, so it may have value to be sold as such or as an independent company.
     
  2. anonymous

    anonymous Guest

    certainly is the trend. PPD is being auctioned off maybe to LabCorp who previously bought out Covance and Parexel announced they will be spending up to 35 million in employee separations costs coming up this year.

    What's with Trump's meeting with the Pharm execs, announcing phase I and II trials to be eliminated to cut down costs??
     
  3. anonymous

    anonymous Guest

    Actually, they mentioned Phase II and III trials.
     
  4. anonymous

    anonymous Guest

    Did QuintilesIMS just sell off a big chunk of the company-the pharma sales division?